Endpoints

Published September 4, 2026 · Updated September 5, 2026

Former I-Mab chief Joan Shen's NeuShen banks $80M+ for 3 brain-health drugs

Biotech Correspondent. A Shanghai and Boston biotech led by a veteran ... That includes a Phase 1 non-hallucinogenic psychedelic and a Phase 2.

Read the full story at Endpoints